RT Journal Article
SR Electronic
T1 Analysis of the clinical characteristics and comorbidities of patients with COPD and home mechanical ventilation
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA526
DO 10.1183/13993003.congress-2023.PA526
VO 62
IS suppl 67
A1 Galdeano Lozano, Marina
A1 Martin Pascual, Adriana
A1 Fernandez Arias, Carmen
A1 Morancho Pallaruelo, Ariadna Ning
A1 Hernandez Guillamet, Guillem Hernandez Guillamet
A1 López Seguí, Francesc
A1 Hernández Biette, Agnes
A1 Aldás Criado, Irene
A1 Marin Muñiz, Antoni
A1 Matute Villacis, Monica
A1 Garcia Olivé, Ignasi
A1 Abad Capa, Jorge
YR 2023
UL http://erj.ersjournals.com/content/62/suppl_67/PA526.abstract
AB Home Mechanical Ventilation (HMV) in patients with COPD and stable hypercapnia is postulated as a recommended treatment but with a low level of evidence. The objective of this study is to assess what clinical characteristics and comorbidities are related to HMV failure and the consequences in terms of economical cost.Observational study of COPD carriers of HMV was performed. We performed a logistic regression using STATA, taking into account comorbidities as dependent variables, and calculating the ODDs Ratio with their confidence intervals (IC). The number of admissions, emergencies and deaths, were obtained through SAP, calculating the associated costs. We included 68 patients, 73% men aged 71 years [55-86 years]. The phenotype was emphysema (60.3%) and the obstruction was 42.3% [15-117%]; the prevalent comorbidity was obstructive sleep apnea. The average pCO2 prior to the start of the HMV was 57 mmHg [38-81] and the average pCO2 after initiation 46 mmHg [36-68]. A significant improvement is objectified (decrease >20% pCO2) after the establishment of HMV. There were 61 admissions, 53 emergency room, 489 consultations and only 2 deaths. The patient with hospital admissions, made a healthcare expenditure of around 9.200 Eur. The expenditure of those who required the least admissions as 126 Eur. Reduction pCO2 compared to the onset of HMV in 51.5% of patients. No comorbidities associated with HMV. FootnotesCite this article as: European Respiratory Journal 2023; 62: Suppl. 67, PA526.This abstract was presented at the 2023 ERS International Congress, in session “Inflammatory endotyping: the macrophage across disease areas”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).